Pollithy S, Höh A, Dobner B, Auffarth GU, Dithmar S. [Are there

Pollithy S, Höh A, Dobner B, Auffarth GU, Dithmar S. [Are there diurnal variations in choroidal thickness?]. Ophthalmologe. 2015 Hoeh AE, Pollithy S, Dithmar S. Factors affecting laser power in retinal Navilas laser treatment. Graefes Arch Clin Exp Ophthalmol. 2014 Höh AE, Beisse C. [Oculomotor system and multiple sclerosis]. Ophthalmologe. 2014 Höh AE, Holz FG, Dithmar S. [Bilateral diffuse uveal melanocytic proliferation in a patient with metastatic breast cancer]. Ophthalmologe. 2014 Höh AE, Beisse F. [Recurrent unilateral pupillary distortion]. Ophthalmologe. 2014 Höh A, Pollithy S, Kernt M, Auffarth GU, Dithmar S. Aktueller Stand der navigierten retinalen Lasertherapie. Z. prakt. Augenheikd. 2013 Höh AE, Dithmar S: Grundlagen der intravitrealen Steroidtherapie. Dithmar S, Höh AE: Intravitreale Steroide bei Zentralvenenverschluss. Dithmar S, Höh AE: Intravitreale Steroide bei Venenastverschluss. In: Hattenbach L-‐O (Hrsg.): Diagnostik und Therapie retinaler Venenverschlüsse. Bremen: UNI-‐MED 2011 Dithmar S, Hoeh AE, Amberger R, Ruppenstein M, Ach T. Light-‐emitting diode technology in vitreoretinal surgery. Retina. 2011 Hoeh AE, Ruppenstein M, Ach T, Dithmar S. OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2010 Ach T, Hoeh AE, Ruppenstein M, Kretz FT, Dithmar S. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-‐related macular degeneration. Retina. 2010 Ach T, Hoeh AE, Schaal KB, Scheuerle AF, Dithmar S. Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2010 Ach T, Thiemeyer D, Hoeh AE, Schaal KB, Dithmar S. Intravitreal bevacizumab for retinal capillary haemangioma: longterm results. Acta Ophthalmol. 2010 Ruppenstein M, Ach T, Höh A, Dithmar S. [Effect of intravitreal bevacizumab on pigment epithelial detachment in occult choroidal neovascularization]. Ophthalmologe. 2010 Schaal KB, Höh AE, Scheuerle A, Dithmar S. [Endophthalmitis after repeated bevacizumab injections]. Ophthalmologe. 2009 Dithmar S, Schaal KB, Höh AE, Schmidt S, Schütt F. [Intravitreal bevacizumab for choroidal neovascularization due to pathological myopia]. Ophthalmologe. 2009 Schaal KB, Höh AE, Scheuerle A, Schütt F, Dithmar S. [OCT-‐based re-‐injections for anti-‐VEGF-‐
treatment for neovascular ARMD]. Ophthalmologe. 2009 Hoeh AE, Ach T, Schaal KB, Scheuerle AF, Dithmar S. Long-‐term follow-‐up of OCT-‐guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009 Schaal KB, Hoeh AE, Scheuerle A, Schuett F, Dithmar S. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol. 2009 Hoeh AE, Schaal KB, Ach T, Dithmar S. Treatment of peripapillary choroidal neovascularization with intravitreal bevacizumab. Eur J Ophthalmol. 2009 Ach T, Höh AE, Amberger R, Dithmar S. [Exposure to light during vitreoretinal surgery. II: Characteristics of endoilluminators]. Ophthalmologe. 2008 Höh AE, Ach T, Amberger R, Dithmar S. [Light exposition in vitreoretinal surgery. I. Basics]. Ophthalmologe. 2008 Höh AE, Schaal KB, Scheuerle A, Schütt F, Dithmar S. [OCT-‐guided reinjection of 2.5 mg bevacizumab for treating macular edema due to retinal vein occlusion]. Ophthalmologe. 2008 Engler C, Schaal KB, Höh AE, Dithmar S. [Surgical treatment of lamellar macular hole]. Ophthalmologe. 2008 Schaal KB, Höh AE, Scheuerle A, Schütt F, Dithmar S. [Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion]. Ophthalmologe.2007 Höh AE, Schaal KB, Dithmar S. [Central and branch retinal vein occlusion. Current strategies for treatment in Germany, Austria and Switzerland]. Ophthalmologe. 2007 Naujokat C, Berges C, Höh A, Wieczorek H, Fuchs D, Ovens J, Miltz M, Sadeghi M, Opelz G, Daniel V. Proteasomal chymotrypsin-‐like peptidase activity is required for essential functions of human monocyte-‐derived dendritic cells. Immunology. 2007 Berges C, Naujokat C, Tinapp S, Wieczorek H, Höh A, Sadeghi M, Opelz G,Daniel V. A cell line model for the differentiation of human dendritic cells. Biochem Biophys Res Commun. 2005

Download Report